Topic
Generic Drug Preemption
28 published works
Drug & Device Law
SDNY Dismisses Generic Prednisone Claims
Kulkarni v. Generics, 2023 U.S.Dist.LEXIS 160730 (S.D.N.Y. Sept. 8, 2023), is an interesting generic preemption (mostly) dismissal involving an “old” (pre-1962) drug. A pro se plaintiff sued five affiliated pharmaceutical companies alleging…
Drug & Device Law
Zantac Chronicles VI – Generic Claims Gone for Good
By Bexis
As we try to keep pace with the unusually fast-moving Zantac MDL, today we review In re: Zantac (Ranitidine) Products Liability Litigation, ___ F. Supp. ___, 2021 WL 2865869 (S.D.…
Drug & Device Law
Mensing Applies to Cross-Claims Too
We all know that absent extraordinary circumstances, failure to warn claims against generic drug manufacturers are preempted under PLIVA, Inc. v. Mensing, 564 U.S. 604 (2011). But as far as…
Drug & Device Law
A Generic Drug Failure to Warn Claim?
No. It can’t be. PLIVA, Inc. v. Mensing, 564 U.S. 604 (2011) took care of that. Just look at our generic preemption scorecard – the proof is there. The warnings…
Drug & Device Law
A Recently Discovered Gem
We found a hidden (at least from us) Georgia federal court decision that we want to discuss because it hits on many of the effective defenses sometimes available to defendants…
Drug & Device Law
Ghostbusters – Phantom “Parallel Claim” Exorcized by Generic Drug Preemption
By Bexis
With claims related to warnings, design, and recall all preempted, plaintiffs seeking to sue makers of generic drugs don’t have many options. After all, as we’ve discussed before, if state common law can’t…
Product Liability & Mass Torts Blog
Supreme Court Declines to Weigh in on Generic Preemption
By Matthew J. Fischer, Jamie Lynn Lanphear
The United States Supreme Court has decided not to review Pliva v. Huck, an Iowa Supreme Court decision that held federal law does not preempt failure to update claims against…
Drug & Device Law
Bullseye
By Bexis
The recent decision in In re Fosamax Products Liability Litigation, 2013 WL 4306434 (S.D.N.Y. Aug. 15, 2013), put it squarely in the red in explaining why no type of design defect claims…
Drug & Device Law
Can’t Blame Philadelphia For These
By Bexis
Because Dechert is involved in the Reglan/metoclopramide litigation, this post is from the Reed Smith side of the blog only. Back in the bad old days (only a couple of years ago), the…
Drug & Device Law
The Generic Preemption Door Stays Open, At Least Until The Facts Matter
We have seen the news that FDA is preparing a proposed rule to change the regulations to permit generic drug manufacturers (ANDA holders) to update their labels based on post-approval…